LRRK2 as a Potential Disease-Modifying Target in Sporadic Parkinson's Disease

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Leucine-rich repeat kinase 2 (LRRK2) is increasingly recognized as a key player in Parkinson's disease (PD).
• Similarities exist between sporadic PD (sPD) and familial LRRK2-linked PD (LRRK2-PD) in phenotype, neuropathology, and biology.
• Genetic variants associated with sPD risk have been identified through genome-wide association studies.

Purpose of the Study:

• To review the role of LRRK2 in sPD, comparing its physiology and pathology with LRRK2-PD.
• To explore the potential of LRRK2 inhibition as a therapeutic strategy for both sPD and LRRK2-PD.

Main Methods:

• Review of current knowledge on LRRK2 in sPD and LRRK2-PD.
• Comparison of LRRK2 activity, endolysosomal function, and α-synuclein accumulation in sPD and LRRK2-PD models.
• Analysis of preclinical data on LRRK2 inhibitors in sPD animal models.

Main Results:

• LRRK2 activity may be elevated in sPD, potentially due to genetic and environmental interactions.
• Increased LRRK2 activity and endolysosomal dysfunction are observed in sPD patients and models.
• LRRK2 inhibitors demonstrate beneficial effects in sPD models, including improved lysosomal function and reduced neurodegeneration.

Conclusions:

• Inhibiting LRRK2 kinase activity represents a promising therapeutic approach for modifying disease progression in both sPD and LRRK2-PD.
• Further clinical studies are needed to evaluate the efficacy of LRRK2 inhibitors and their impact on lysosomal function in PD patients.